1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ)

CALTX.ST
Calliditas Therapeutics AB (publ)SE flagStockholm Stock Exchange
208.00
SEK
+1.80
- -
11.24BMarket Cap
Calliditas Therapeutics AB (publ)
CALTX.ST
(Stockholm Stock Exchange)

Recent

price

208.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
5
0.02
4.51
15.14
22.49
29.83
Revenue per Share
-0.77
-0.86
-2.91
-2.54
-0.88
-9.66
-9.84
-7.78
-8.69
-8.95
Basic EPS, GAAP
-0.74
-0.84
-2.28
-2.47
-2.36
-6.89
-9.53
-5.92
-8.34
-4.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.64
-3.5
-10.71
-8.75
-13.17
-20.43
-28.02
-34.59
-42.91
- -
Book Value per Share
0.27
-0.21
1.11
11.91
20.9
18.66
11.98
5.33
-2.69
-6.8
Tangible Book Value per Share
66
66
30
52
37
45
51
53
54
54
Basic Weighted Avg Shares
- -
- -
- -
- -
185
1
229
803
1,207
1,601
Sales/Revenue/Turnover
- -
- -
- -
- -
-15.08
-43,732.38
-226.02
-49.68
-33.92
-24.32
Operating Margin (%)
- -
- -
- -
- -
2
3
34
13
49
- -
Depreciation Expense
-51
-57
-87
-132
-33
-433
-500
-412
-466
-480
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-17.63
-49,598.86
-218.14
-51.35
-38.63
-30
Profit Margin (%)
18
-15
33
618
768
931
877
1,087
868
725
Working Capital
- -
- -
- -
- -
4
1
213
729
967
1,008
LT Debt
18
-14
33
618
788
1,256
1,008
766
335
107
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
940
986
982
LT Finance Leases
27
30
26
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
6,822
6,086
11,036

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,275
1,099
1,154
Cash, Cash Equivalents & STI
974
810
797
Accounts Receivable, Net
181
183
223
Inventories
20
29
40
Total Current Liabilities
407
408
430
Payables & Accruals
376
375
403
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.63%
-56.31%
Free Cash Flow
- -
57.32%
42.56%
Net Income, GAAP
- -
233.24%
13.08%
Sales/Revenue/Turnover
- -
- -
50.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
50
64
260
429
803
2023
191
269
295
452
1,207
2024
295
560
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-3.95
-3.62
-0.17
- -
-7.78
2023
-3.49
-1.71
-3.14
-0.34
-8.69
2024
-4.59
-0.88
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Shanghai Haohai Biological Technology Co., Ltd. (688366.SS)
Pure Biologics Spólka Akcyjna (PUR.WA)
Jupiter Neurosciences, Inc. (JUNS)
Carna Biosciences, Inc. (4572.T)
Pascal Biosciences Inc. (PSCBF)
Corium International, Inc. (CORI)
Business
Calliditas Therapeutics AB (publ) (Nasdaq Stockholm: CALTX) operates as a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for orphan indications, particularly rare renal and hepatic diseases including IgA nephropathy (IgAN). The company offers TARPEYO (budesonide) delayed release capsules, approved by the US FDA for reducing the loss of kidney function in adults at risk of rapidly progressing IgAN; Kinpeygo (budesonide) delayed release capsules, fully approved by the European Commission for IgAN treatment and marketed in the EEA, UK and Switzerland by partner STADA Arzneimittel AG; and investigational NOX inhibitor setanaxib in Phase 2 for hereditary nephritis and cancer indications; as well as partnerships for Nefecon commercialization including launches by Everest Medicines in China and Viatris in Japan. Founded in 2004 and headquartered in Stockholm, Sweden, Calliditas conducts operations across the US, Europe, China and Japan with offices in New York and Hoboken. In 2024, Asahi Kasei Corporation completed the acquisition of a 93.3% stake, positioning Calliditas as a wholly-owned subsidiary to expand global specialty pharma presence in renal and autoimmune diseases; partner Everest Medicines launched Nefecon commercially in China in May; STADA secured full European approval for Kinpeygo in July following positive CHMP opinion; Viatris initiated a Phase 3 Nefecon trial in Japan; positive topline Phase 2 results emerged for setanaxib in head and neck cancer; and TARPEYO gained an additional seven-year US orphan drug exclusivity while securing new patents for setanaxib in cancer.